Table 2.
Laboratory characteristics of patients with RP at the active and inactive stages in cohort 1.
| Laboratory parameters | Active (n = 35) | Inactive (n = 43) | p-value | Laboratory parameters | Active (n = 35) | Inactive (n = 43) | p-value |
|---|---|---|---|---|---|---|---|
| Inflammatory parameters/cytokines | |||||||
| CRP (mg/L) | 8.22 (25.98) | 1.05 (2.43) | <0.001 | ESR (mm/h) | 16 (37) | 6 (12) | <0.001 |
| Albumin (g/L)a | 40.31 (4.23) | 44.71 (3.54) | <0.001 | CAR (10−3) | 0.19 (0.70) | 0.02 (0.05) | <0.001 |
| IL-6 (pg/ml) | 5.90 (14.63) | 2.20 (2.98) | 0.034 | C3 (g/L) | 1.36 (0.31) | 1.03 (0.29) | 0.010 |
| WBC-related parameters | |||||||
| WBC (×109/L) | 9.76 (4.50) | 8.05 (4.33) | 0.057 | ||||
| Neutrophil (×109/L) | 6.73 (3.16) | 5.00 (3.34) | 0.024 | Neutrophil (%)a | 70.45 (9.85) | 64.81 (11.08) | 0.021 |
| Monocyte (×109/L)a | 0.51 (0.22) | 0.45 (0.14) | 0.118 | Monocyte (%)a | 5.51 (1.74) | 5.87 (1.74) | 0.369 |
| Lymphocyte (×109/L) | 1.76 (1.23) | 1.94 (0.83) | 0.491 | Lymphocyte (%)a | 22.32 (8.70) | 27.73 (10.32) | 0.016 |
| Basophil (×109/L) | 0.03 (0.03) | 0.03 (0.02) | 0.109 | Basophil (%) | 0.20 (0.40) | 0.40 (0.30) | 0.007 |
| Eosinophil (×109/L) | 0.04 (0.04) | 0.05 (0.07) | 0.162 | Eosinophil (%) | 0.40 (0.55) | 0.90 (0.90) | 0.064 |
| NLR | 3.50 (2.58) | 2.46 (1.57) | 0.013 | LMR | 3.97 (2.80) | 4.54 (2.83) | 0.170 |
| Platelet-related parameters | |||||||
| Platelet (×109/L) | 305 (140.5) | 235 (83.5) | 0.002 | PLR | 178.53 (132.01) | 115.79 (88.36) | 0.020 |
RP, relapsing polychondritis; HC, healthy control; CRP, C-reactive protein; CAR, CRP to albumin ratio; ESR, erythrocyte sedimentation rate; IL, interleukin. TNF-α, tumor necrosis factor α; WBC, white blood cell; LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; C3, complement 3.
a
Represents normally distributed data, expressed as mean (SD). Others are non-normally distributed data, expressed as median (IQR), IQR = Q3–Q1.